Castle Biosciences to Present at Upcoming Investor Conferences | national company

FRIENDSWOOD, Texas–(BUSINESS WIRE)–March 1, 2022–

Castle Biosciences, Inc. (Nasdaq: CSTL), a company that improves health through innovative tests that guide patient care, today announced that Derek Maetzold, President and Chief Executive Officer, and Frank Stokes, Director financial, were scheduled to present an overview of the company at the following upcoming investor conferences:

  • 42nd Annual Cowen Health Care Conference on March 8, 2022 at 2:50 p.m. EST.
  • KeyBanc Capital Markets Virtual Life Sciences and Medtech Investor Forum on March 22, 2022 at 9:45 a.m. EST.

Live audio webcasts of the company’s presentations will be available by visiting the Castle Biosciences website at https://ir.castlebiosciences.com/events-presentations/default.aspx. Webcast replays will be available for two weeks after the live streams end.

About Castle Biosciences

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company that improves health through innovative tests that guide patient care. The Company aims to transform disease management by putting people first: patients, clinicians, employees and investors.

Castle’s current portfolio includes tests for skin cancers, uveal melanoma and Barrett’s esophagus. Additionally, the Company has active research and development programs for testing in other diseases of high clinical need, including its test in development to predict systemic therapeutic response in patients with moderate to severe psoriasis, atopic dermatitis and related conditions. To learn more, visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, Twitter and Instagram.

DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, myPath Melanoma, DecisionDx DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeq and TissueCypher are registered trademarks of Castle Biosciences, Inc.

See the source version on businesswire.com: https://www.businesswire.com/news/home/20220301005278/en/

CONTACT: Investor Contact:

Camille Zuckero

[email protected] contact:

Allison Marshall

[email protected]

KEYWORD: UNITED STATES NORTH AMERICA TEXAS

INDUSTRY KEYWORD: ONCOLOGY GENETIC HEALTH OTHER HEALTH GENERAL HEALTH BIOTECHNOLOGY

SOURCE: Castle Biosciences, Inc.

Copyright BusinessWire 2022.

PUBLISHED: 03/01/2022 07:00 / DISK: 03/01/2022 07:02

http://www.businesswire.com/news/home/20220301005278/en

Copyright BusinessWire 2022.